Physician profile
Robert A Nathan
NPI 1487648077
$130,361.52
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $12K · 2021: $11K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124,233.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,936.81 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $138.13 | 2019 | |
| Csl Behring | $22.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.90 | 2019 | |
| Optinose US, INC. | $12.99 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.